22/07/2020 At the beginning of July, the BioSIS department (IRTB project) acquired a multispectral camera. Located on the premises of the CRAN's Medicine site, it was purchased as part of the structuring of the PhotoVivo optical platform of the 2015-2020 State-Regional Plan Contract "Technological Innovations, Modelling & Personalised Medicine (CPER IT2MP).
The human eye makes it possible to visualise a scene (an object) thanks to intensity and colour sensors located on the retina. These sensors enable it to distinguish the 6 colours of the rainbow (from violet to red) and their combinations (spectral resolution of about 20 nm) with a spatial resolution of about 0.1 mm. The multispectral camera provides spectral information, i.e. it allows each pixel to be associated with a complete optical spectrum (a reflectance intensity value approximately every 3 nm in the 470-900 nm spectral band). The Snapscan LS150+ camera from IMEC is equipped with a 7 Mega-pixel sensor, providing access to a spatial resolution that is unequalled in today's multispectral camera market. The counterpart to this high level of spatial resolution is its acquisition speed, which is limited to around 5 frames per second (or even less depending on lighting conditions).
The members of the IRTB project team of the BioSIS department will use this camera to evaluate its capacity to aid in the intra-operative diagnosis of skin carcinomas (skin cancers). 3 people from CRAN have been trained in the use of the camera purchased from the company ProLite. Other applications can of course be envisaged.
After the acquisition of an imaging device using the OCT method (Octav, Damae Medical company), a spectroradiometer with dual monochromators (IDR300, Bentham) and a non-contact optical imaging device for the construction of panoramic images (IPAM, SD Innovation) in 2019, this camera is one of the six pieces of equipment purchased as part of the CPER IT2MP. Its purpose is to structure the "PhotoVivo" optical platform for the characterisation of biological tissues by multispectral label-free (unmarked) optical methods applied to cancer diagnosis.
The financers of the CPER are the State, the Grand Est Region and the ERDF. Co-financing is provided by the Ligue Contre le Cancer (League Against Cancer).
